ASCO 2024
Check out the novel and groundbreaking science presented at the 2024 ASCO Annual Meeting, taking place May 31-June 4, 2024, in Chicago, IL.
Primary care providers are highly involved in opioid prescribing for HNC survivors.
Some patients are unaware that metastatic breast cancer is incurable and that their treatment has no established end date.
Edmonton Symptom Assessment System completion rates need to be improved in patients with HNC.
One year of immunotherapy is optimal for treating patients with advanced melanoma.
Pembrolizumab use is increasing among patients with recurrent cervical cancer.
Eribulin is noninferior to trastuzumab and pertuzumab plus taxane in treating HER2-positive breast cancer.
Episodic future thinking may help breast cancer survivors lose weight.
Sexual health concerns are highly prevalent in women following breast cancer diagnosis.
Patients with head and neck cancer have increased rates of suicide compared with patients with other cancers.
An objective manual screening process may enhance diversity in gynecologic cancer clinical trial enrollment.
Medicaid expansion and improved access to health care services facilitate diagnosing melanoma at an early stage.
Advertisement
Advertisement
